Young adults, particularly university students, face an increased risk from meningococcal meningitis and septicaemia. New data from the UK Health Security Agency (UKHSA) reveals that Meningitis B (MenB) caused 97% of invasive meningococcal disease cases in 15 to 24-year-olds in England during 2025 to 2026, accounting for 93 out of 96 cases.
The UKHSA is advising freshers to ensure they receive two doses of the MenB vaccine before term begins. First-year university students are at a risk of meningococcal disease approximately seven times higher than young people of a similar age who do not attend university.
In response to outbreaks in Kent, Dorset, and Berkshire, a one-off MenB vaccination programme was introduced this summer, targeting school leavers and first-year university and higher education undergraduates. As of August 31, 2026, 246,089 doses of the MenB vaccine have been administered to young people, though many school leavers and first-year undergraduates are still eligible.
Dr Shamez Ladhani, Consultant Epidemiologist at UKHSA, highlighted that university is a time when young people are at greater risk due to close contact. Vinny Smith, Chief Executive of Meningitis Research Foundation, and Dr Tom Nutt, Chief Executive at Meningitis Now, both emphasised the importance of eligible young people taking up the MenB vaccine offer.
While the vaccine offers protection against most meningococcal strains, it does not cover all infections that can cause meningitis and septicaemia. It is crucial for everyone to recognise the symptoms, which include a high temperature, cold hands and feet, vomiting, confusion, and a rash, and to seek medical advice immediately.